Therefore, investigations have focused on systemic STING agonists, which carry a risk of causing cytokine release syndrome and acute inflammation if their activity is not restricted to the tumor site as well as the potential for overactivation of immune cells, which might induce adverse effects as discussed later. Here, STING1 is linked to neoplasm.